LTX-315
An investigational membrane-disrupting peptide studied by injection into tumors.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Clinical Trials
Investigational and not FDA-approved as a cancer treatment.
- Human data
- Limited
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
An investigational membrane-disrupting peptide studied by injection into tumors.
Investigational and not FDA-approved as a cancer treatment.
Local biological activity and an uncontrolled early trial do not establish effective systemic cancer treatment.
Why It's Being Studied
- Oncolytic peptides
- Tumor immune response
Mechanism of Action
Local tumor-cell disruption is intended to release tumor material and stimulate antitumor immune responses.
Local tumor-cell disruption is intended to release tumor material and stimulate antitumor immune responses. Local biological activity and an uncontrolled early trial do not establish effective systemic cancer treatment.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Oncolytic peptides
- Tumor immune response
- Intratumoral clinical research
Evidence Summary
A phase 1 study of 39 patients reported local tumor and immune changes; it did not establish a survival benefit.
Higher tiers carry more weight. Filled tiers have evidence for LTX-315; tap to read it.
- A phase 1 study of 39 patients reported local tumor and immune changes; it did not establish a survival benefit.
1 cited sources.
- Phase 1 trial1
Human clinical evidence
- A phase 1 study of 39 patients reported local tumor and immune changes; it did not establish a survival benefit.
Reported Adverse Events in Research
- Hypotension and serious hypersensitivity or anaphylaxis occurred in early clinical work.
Limitations of Current Evidence
- Local biological activity and an uncontrolled early trial do not establish effective systemic cancer treatment.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| LTX-315 | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Clinical Trials | FDA Approved for Specific Indication |
| Human data | Limited | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Intratumoral clinical research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Phase 1 trial
LTX-315 — phase 1 trial